Open Orphan PLC Result of General Meeting (7024P)

TIDMORPH

RNS Number : 7024P

Open Orphan PLC

11 June 2020

Open Orphan plc

("Open Orphan", or the "Company")

Result of General Meeting

Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge study models, is pleased to announce that at the Company's General Meeting held earlier today in relation to the Fundraising, all of the Resolutions put to the meeting were duly passed.

The Conditional Fundraise remains conditional on Admission of the relevant Conditional Fundraising Shares to AIM and Euronext Growth, which is expected to take place at 8.00 a.m. on Friday 12 June 2020.

Total Voting Rights

Following the Admission of the Conditional Fundraising Shares, the total number of Ordinary Shares in the Company in issue will be 663,860,098. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure and Transparency Rules.

Unless otherwise defined, capitalised terms used in this announcement are as defined in the Circular.

For further information please contact

 
                                                      +353 (0)1 644 
 Open Orphan plc                                               0007 
 Cathal Friel, Executive Chairman 
 Arden Partners plc (Nominated Adviser and Joint     +44 (0)20 7614 
  Broker)                                                      5900 
 John Llewellyn-Lloyd / Benjamin Cryer / Dan 
  Gee-Summons 
                                                    +44 (0) 20 7220 
 finnCap plc (Joint Broker)                                    0500 
 Geoff Nash / James Thompson / Charlie Beeson 
                                                      +353 (0)1 679 
 Davy (Euronext Growth Adviser and Joint Broker)               6363 
 Anthony Farrell 
                                                     +44 (0)20 3757 
 Camarco (Financial PR)                                        4980 
 Tom Huddart / Hugo Liddy

Notes to Editors - Open Orphan:

Open Orphan is a rapidly growing niche CRO pharmaceutical services company which is a world leader in the testing of vaccines and antivirals through the use of human challenge clinical trials. Conducted from Europe's only 24-bedroom quarantine clinic with onsite virology providing individually isolated rooms and connected to our specialist laboratory facility. Which offers highly specialised virology and immunology laboratory services to support pre-clinical and clinical respiratory drug, antiviral, and vaccine discovery and development. Reliable laboratory analysis underpinned by scientific expertise is essential when processing and analysing clinical samples. Robust quality processes support our team of scientists in the delivery of submission ready data.

The Company has a leading portfolio of 8 viral challenge study models which are: 2 FLU, 2 RSV, 1 HRV, 1 Asthma, 1 cough and 1 COPD viral challenge models. As announced in early March, Open Orphan is rapidly advancing a number of Coronavirus challenge study models and expects to be helping many COVID-19 vaccine development companies to test their vaccines. No other company in the world has such a portfolio, with only two competitors globally having 1 challenge study model each. In June 2020 hVIVO COVID Clear Test was launched, the most accurate antibody test available to UK employers, helping them to get their people back to work.

Open Orphan comprises of two commercial specialist CRO services businesses, hVIVO and Venn Life Sciences , and is developing an early stage orphan drug genomics data platform business. This platform captures valuable genetic data from patient populations with specific diseases with designated orphan drug status and incorporating AI tools. In June 2019, Open Orphan acquired AIM-listed Venn Life Sciences Holdings plc in a reverse take-over and in January 2020 it completed the merger with hVIVO plc. Venn, as an integrated drug development consultancy, offers CMC (chemistry, manufacturing and controls), preclinical, Phase I & II clinical trials design and execution. The merger with hVIVO created a European full pharma services company broadening the Company's customer base and with complementary specialist CRO services, widened the range of the Company's service offerings.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

ROMFBMBTMTBBBJM

(END) Dow Jones Newswires

June 11, 2020 07:15 ET (11:15 GMT)

Hvivo (LSE:HVO)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024